Nasal application of rBet v 1 or non-IgE-reactive T-cell epitope-containing rBet v 1 fragments has different effects on systemic allergen-specific antibody responses

Journal of Allergy and Clinical Immunology

Volumn 126, Issue 6, 2010, Pages

  Egger, Cornelia ^a   Horak, Friedrich ^a   Vrtala, Susanne ^a   Valenta, Rudolf ^a   Niederberger, Verena ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; POLLEN ANTIGEN;

ALLERGIC RHINITIS; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; BIRCH; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DISEASE SEVERITY; HUMAN; IMMUNOGLOBULIN PRODUCTION; LETTER; LYMPHOCYTE PROLIFERATION; NOSE PROVOCATION TEST; POLLEN ALLERGY; PRIORITY JOURNAL; RHINOMANOMETRY; T LYMPHOCYTE;

EID: 78649828969     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2010.06.008     Document Type: Article

References (11)

1. S.S. Saini, and D. MacGlashan How IgE upregulates the allergic response Curr Opin Immunol 14 2002 694 697
2. R.J. van Neerven, E.F. Knol, A. Ejrnaes, and P.A. Würtzen IgE-mediated allergen presentation and blocking antibodies: regulation of T-cell activation in allergy Int Arch Allergy Immunol 141 2006 119 129
3. T. Kawakami, and S.J. Galli Regulation of mast-cell and basophil function and survival by IgE Nat Rev Immunol 2 2002 773 786
4. V. Niederberger, J. Ring, J. Rakoski, S. Jager, S. Spitzauer, and P. Valent Antigens drive memory IgE responses in human allergy via the nasal mucosa Int Arch Allergy Immunol 142 2007 133 144
5. F.L. Dente, E. Bacci, A. Di Franco, D. Giannini, B. Vagaggini, and P.L. Paggiaro Natural exposure to pollen reduces the threshold but does not change the pattern of response to the allergen in allergic subjects Respir Med 94 2000 1073 1078
6. S.R. Durham, W.H. Yang, M.R. Pedersen, N. Johansen, and S. Rak Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis J Allergy Clin Immunol 117 2006 802 809
7. V. Niederberger, F. Horak, S. Vrtala, S. Spitzauer, M.T. Krauth, and P. Valent Vaccination with genetically engineered allergens prevents progression of allergic disease Proc Natl Acad Sci U S A 101 2004 14677 14682
8. I. Pree, J. Reisinger, M. Focke, S. Vrtala, G. Pauli, and M. van Hage Analysis of epitope-specific immune responses induced by vaccination with structurally folded and unfolded recombinant Bet v 1 allergen derivatives in man J Immunol 179 2007 5309 5316
9. S. Vrtala, K. Hirtenlehner, L. Vangelista, A. Pastore, H.G. Eichler, and W.R. Sperr Conversion of the major birch pollen allergen, Bet v 1, into two non-anaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy J Clin Invest 99 1997 1673 1681
10. V. Niederberger, P. Stübner, S. Spitzauer, D. Kraft, R. Valenta, and K. Ehrenberger Skin test results but not serology reflect immediate type respiratory sensitivity: a study performed with recombinant allergen molecules J Invest Dermatol 117 2001 848 851
11. D.A. Stern, J. Riedler, D. Nowak, C. Braun-Fahrlander, I. Swoboda, and N. Balic Exposure to a farming environment has allergen-specific protective effects on TH2-dependent isotype switching in response to common inhalants J Allergy Clin Immunol 119 2007 351 358